Tingting Zhou

Dr. Tingting Zhou


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2022 in AMB Express
Verified
Journal Article
Open access
PDF file
SGShikun Ge
Shikun Ge
RWRao Wu
Rao Wu
TZTingting Zhou
Tingting Zhou
XLXiang Liu
Xiang Liu
JZJin Zhu
Jin Zhu
XZXiaoying Zhang
Xiaoying Zhang
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread globally, a series of vaccines, antibodies and drugs have been developed to combat coronavirus disease 2019 (COVID-19). High specific antibodies are powerful tool for the development of immunoassay and providing passive immunotherapy against SARS-CoV-2 and expected with large scale production. SARS-CoV-2 S1 protein was expressed in E. coli BL21 and purified by immobilized metal affinity chromatography, as antigen used to immunize hens, the specific IgY antibodies were extracted form egg yolk by PEG-6000 precipitation, and the titer of anti-S1 IgY antibody reached 1:10,000. IgY single chain variable fragment antibody (IgY-scFv) was generated by using phage display technology and the IgY-scFv showed high binding sensitivity and capacity to S1 protein of SARS-CoV-2, and the minimum detectable antigen S1 protein concentration was 6 ng/µL. The docking study showed that the multiple epitopes on the IgY-scFv interacted with multiple residues on SARS-CoV-2 S1 RBD to form hydrogen bonds. This preliminary study suggests that IgY and IgY-scFv are suitable candidates for the development of immunoassay and passive immunotherapy for COVID-19 to humans and animals.

19 June 2023 in Chemosensors
Verified
Journal Article
Open access
PDF file
LLLin Lin
Lin Lin
TZTingting Zhou
Tingting Zhou
JZJin Zhu
Jin Zhu
Shou-Nian DingShou-Nian Ding
Shou-Nian Ding
The high infectivity, difficulty to diagnose, and high drug resistance of melioidosis limited the timeliness of treatment. Lateral flow assay (LFA) was operated in this research to provide an instant diagnosis method, and a fast antibody rapid matching test strategy based on LFA was developed to select the most sensitive and specific pair of antibodies. Compared to the traditional ELISA method, the new matching strategy limits the pairing time to 3 h without any complex instruments. The rapid pairing test strategy is a universal strategy that is suitable for various sandwich immune antigen pairings. To fasten the test of the test strips, dry fluorescence immunoassay analyzer (DFIA) was designed and applied. The equipment also simplifies the process of data acquisition. Finally, the concentration gradient test was operated, and the detection lines and limits were presented.